Robert Daniels

Robert Daniels is an experienced professional in the biotech and pharmaceutical sectors, currently serving as a Venture Partner at Brandon Capital Partners since August 2021, focusing on early-stage biotech opportunities. Prior to this, Robert held the position of Head Elastagen at AbbVie from May 2020 to June 2021, where responsibilities included integrating the Elastagen business into Abbvie's Asset Strategy post-acquisition of Allergan. Similarly, during tenure at Allergan from April 2018 to April 2020, Robert led the integration of Elastagen's business and pipeline products across multiple functional areas. Robert was also the Chief Executive of Elastagen Pty Ltd from October 2008 to March 2018, overseeing its growth from a startup to a global entity and facilitating its acquisition by Allergan for approximately A$350M. Additional experience includes roles at PharmaVentures as Associate and VP Asia Pacific and as Chief Commercial Officer at NovaThera Ltd. Educational qualifications comprise a PhD in Developmental Biology and Embryology from UCL, an MEI from Swinburne University of Technology, and a BSc in Physiology from the University of Leeds.